Loading stock data…
KALA BIO, Inc. (KALA)
$0.53+0.02 (+4.82%)
Market OpenUpdated 12:33 PM EDT
KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
KALA BIO, Inc. in the Healthcare sector is trading at $0.53 with a market capitalization of $18M. The stock is currently near its 52-week low of $0.49, remaining 96.1% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 15 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 15) — potential for technical mean-reversion
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$1.80M↑ | -$10.22M↓ | -$10.18M↑ | -$10.33M↓ | -$8.30M |
| Net Income | -$1.62M↓ | $686,000↑ | -$7.56M↑ | -$11.15M↓ | -$8.95M |
Peer Comparison
JNJUNHPFE
Fundamentals
KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$17.87M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-2.28
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-182.64%
Volume
Today's trading volume
111,746
Recent News
Kala Bio Signs Exclusive U.S. Distribution Agreement for Virotek Ophthalmology Genetic Tests
Kala Bio, Inc. (NASDAQ:KALA) and Virotek Inc.
Kala Bio Targets Near-Term Revenue With Virotek Ophthalmology Genetic Testing Partnership
The proposed exclusive U. S. distribution agreement would give Kala a commercial opportunity in its established ophthalmology market while leaving Virotek responsible for laboratory operations and clinical reporting.
BC-Most Active Stocks
Elong Power Holding Ltd. 79,546,080 0.0559
Top Midday Gainers
Q32 Bio's (QTTB) shares doubled amid heavy trading after the company said Monday it sold alopecia ar
KALA BIO: Q3 Earnings Snapshot
ARLINGTON, Mass. AP) — KALA BIO, Inc. KALA) on Wednesday reported a loss of $7.6 million in its third quarter.